Hikal share price

Shares of Hikal surged over 12 per cent in early deals on BSE on Tuesday (May 30), a day after the company released its March quarter scorecard which showed healthy year-on-year (YoY) growth in the company's profit, thanks to softening of raw material prices and operational improvement initiatives. The stock opened nearly 5 per cent higher at ₹296.10 against the previous close of ₹283.15 on BSE and rose over 12 per cent to the level of ₹317.65 within the first 10 minutes of trade. Besides, ₹0.60 per equity share) for the financial year 2023. The total dividend for the year is 60 per cent of the paid-up capital (i.e. ₹1.20 per equity share). The company said its Panolisite underwent a US FDA audit which was concluded with ‘Zero’ 483 observations. Among the segments, Hikal said the pharmaceutical sales were flat and stood at ₹309 crore in Q4FY23 as compared to ₹308 crore in Q4FY22. However, due to some operational initiatives, the segment saw an improvement in margins. The company said its new multipurpose plant for animal health is on track at Panoli, Gujarat and is expected to be completed in the first half of FY24. On the other hand, crop protection segment sales grew by 22 per cent to ₹236 crore in Q4FY23 against ₹194 crore in the corresponding quarter last year. The new multipurpose facility at Panoli, Gujarat is reaching completion; currently, stabilising and commissioning activity is going as per the plan, said the company.

Find Stock Hikal (HIKAL) Experts Views (BUY SELL) [2023] (HIKAL) share price target ["experts views"] BUY/SELL -NSE stock exchange Hikal HIKAL Experts view BUY SELL, share price targets for short, mid, long term 2023 NSE stock exchange NSE stock HIKAL Hikal experts views & buy sell levels signals are here. Stock listed under Hikal share price opened at: 318.85 Hikal share price closed at: 317.35 Hikal share price made a High of: 321.55 Hikal share price made a low of: 315.00 52 week High of Hikal: 595.00 52 week Low of Hikal: 212.00 HIKAL is trading in the lower range of yearly prices. Went as high as 329.00 in the last three months (quarter) Went as low as 260.75 in the last three months (quarter) HIKAL is trading in the upper range of the quarterly prices. The session was a bearish session and prices moved within a range of 315.00 and 321.55, with a volume of -5.15% compared to average volume that Hikal normally has. The NSE share HIKAL Hikal appears to be moving downwards constantly. Keep reading experts views on Hikal below for shortterm to longterm HIKAL share prices targets and buy sell signals, points & levels. NSE HIKAL Experts Views Hikal Buy Sell Signals The share prices have been falling shortly. An initial buy or sell signal has not been generated yet. However, if a BUY/SELL signal is mentioned below then you can choose to take a trade with a strict stoploss. NSE HIKAL Experts Views Hikal MACD Convergence Divergence Hikal fast MACD line is above the slow signal...

Hikal Ltd's share price surged by nearly 11 percent in early trade on May 30, following the company's announcement of robust financial figures for the quarter ended March 2023. The agrochemicals and pharmaceutical company reported a significant year-on-year (YoY) increase of 74 percent in net profit at Rs 36 crore for the March quarter of the financial year 2023. Sequentially, the net profit grew by 37 percent in Q4 FY23, driven by a better product mix. During the March quarter, total revenue reached Rs 545 crore, marking a 9 percent increase from Rs 502 crore in the corresponding period of the previous fiscal year. The growth in revenue was attributed to a change in the product mix and increased demand for select products, as stated in the regulatory filing. At the operating level, EBITDA (earnings before interest, tax, depreciation, and amortization) saw a remarkable jump of 48 percent to Rs 90 crore, compared to Rs 61 crore during the same period a year ago. Sequentially, the recovery in margins was driven by the softening of raw material prices, various operational improvement initiatives, and enhanced efficiencies resulting from ongoing business excellence programs across the value chain. In terms of segment-wise performance, the revenues for the pharmaceutical business remained flat at Rs 309 crore YoY, while the crop protection business witnessed a 22-percent YoY growth, amounting to Rs 236 crore in Q4 FY23. The EBIT margins showed a 21 percent YoY growth in the pha...

Hikal is predominantly a B2B player that provides intermediates and active ingredients to global pharmaceutical, animal health, crop protection and specialty chemical companies. • Pharma and crop protection are 58% and 42% of operating revenues, respectively. The pharma business is currently divided in 50:50 ratio of APIs and CDMO. Animal health business accounts for 20-25% of CDMO business • In crop protection, 69% revenues are derived from CDMO while remaining is from proprietary products, specialty chemicals & specialty biocides • One of the largest suppliers of Gabapentin API (CNS) and in crop protection, one of the largest suppliers of Thiabendazole (TBZ) Description • Hikal Limited is an Indian company that deals in pharmaceuticals, animal health, crop protection, Biotech, and special chemical products. It has a market capitalisation of Rs. 5369.76 crore as of April 7, 2022. It was incorporated on July 8, 1988 as a manufacturer and marketer of chemicals, dyes, pharmaceuticals, and pesticides. The quarterly revenue for the period of September to December 2021 for Hikal Limited was Rs. 515 crore. The company is listed on the Bombay Stock Exchange (BSE) as well as the National Stock Exchange (NSE) under the number 524735 and scrip code HIKAL. Hikal has five manufacturing units in India at Taloja and Mahad in Maharashtra, Panoli in Gujarat, and Jigani in Bengaluru. It also has a world-class research and technology institute in Pune. The company operates primarily in the ...

Hikal Ltd. engages in the manufacture of chemical intermediates, specialty chemicals, active pharma ingredients, and contract research activities. It operates through the Crop Protection and Pharmaceuticals segments. The Crop Protection segment involves in manufacturing of intermediates and active ingredients. The Pharmaceuticals segment offers contract development and manufacturing; APIs and intermediates; animal health, and project management. The company was founded by Jai Hiremath on July 8, 1988 and is headquartered in Mumbai, India. After a decent run to 726 in sept'21 it has corrected and made a bottom around 240-50 in jul'22. Since than a good accumulation is going on and higher high kind of formation is in progress. Meanwhile there is a rumour of some family dispute among kalyani group management over family asset pool. Keep After a decent run to 726 in sept'21 it has corrected and made a bottom around 240-50 in jul'22. Since than a good accumulation is going on and higher high kind of formation is in progress. Meanwhile there is a rumour of some family dispute among kalyani group management over family asset pool. Keep Hikal Ltd. provides solutions related to Pharmaceuticals, Crop protection, Specialty Chemicals and Research & Technology. Hikal has five manufacturing facilities in India at Maharashtra, Gujarat, Karnataka and a Research & Technology centre at Maharashtra. Hikal CMP is 319.45. Negative aspects of Hikal Ltd. provides solutions related to Pharmaceuti...